Stonkhead: Why do millionaire investors bother selling courses?
Link copied to
Stockhead’s biggest market (t)memes of the week.
It was not a good week to invest in biotech Mesoblast (ASX:MSB).
Mesoblast shares took a dive earlier in the week after a Mesoblast stem cell treatment failed to meet a primary endpoint.
Shares plunged again after a huge setback to a different clinical trial testing the use of its stem-cell infusion on severely ailing US COVID-19 patients.
At 11.52am on Friday, Mesoblast shares were down 36.4 per cent to $2.40 — their lowest level since late April.
Enough depressing content. Here are more punters making ridiculous amounts of money on Tesla.
…the portfolio mainstays of legendary investor Warren Buffett over the last 25 years:
And finally, a (non) answer to the age-old question – if you are a millionaire investor, why bother selling courses?
Tough scene for this financial guru. pic.twitter.com/EGmTWnQRKa
— TikTok Investors (@TikTokInvestors) December 17, 2020